Beyond Air, Inc. (NASDAQ:XAIR – Get Rating) Director Robert Carey bought 10,000 shares of Beyond Air stock in a transaction dated Wednesday, November 16th. The shares were acquired at an average price of $6.00 per share, with a total value of $60,000.00. Following the completion of the purchase, the director now owns 752,323 shares in the company, valued at approximately $4,513,938. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Robert Carey also recently made the following trade(s):
- On Friday, November 18th, Robert Carey bought 20,000 shares of Beyond Air stock. The shares were acquired at an average price of $5.80 per share, with a total value of $116,000.00.
Beyond Air Price Performance
Shares of XAIR opened at $5.81 on Monday. The business’s fifty day moving average price is $7.26 and its 200 day moving average price is $7.63. Beyond Air, Inc. has a 12-month low of $4.78 and a 12-month high of $16.41. The stock has a market capitalization of $173.78 million, a PE ratio of -3.25 and a beta of -0.12.
Hedge Funds Weigh In On Beyond Air
Large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. bought a new position in Beyond Air during the first quarter worth $94,000. Coombe Bender & Co LLC bought a new position in Beyond Air during the second quarter worth $101,000. Mitchell Mcleod Pugh & Williams Inc. bought a new stake in Beyond Air in the third quarter valued at $163,000. Meitav Dash Investments Ltd. lifted its stake in Beyond Air by 96.0% in the first quarter. Meitav Dash Investments Ltd. now owns 26,542 shares of the company’s stock valued at $179,000 after buying an additional 13,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Beyond Air in the third quarter valued at $198,000. 16.45% of the stock is currently owned by institutional investors.
About Beyond Air
Beyond Air, Inc operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.
- Get a free copy of the StockNews.com research report on Beyond Air (XAIR)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.